ECM-Binding Peptides for Selective Tumor Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Targeting FN-EDB and TNC-C in the tumor microenvironment has proven difficult, necessitating compositions and therapeutics that can effectively bind to these ECM proteins for enhanced drug delivery and diagnostic imaging.
Innovation Solution
Development of peptides with specific amino acid sequences, such as PPRRGLIKLKTS, TSKQNSR, and AGRGRLVR, which can selectively bind to FN-EDB and/or TNC-C, allowing for targeted delivery of therapeutic or detectable agents to tumors and extracellular matrix.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibodies are used as affinity ligands for targeting, then tumor site drug concentration is increased, but manufacturing cost increases and tissue penetration decreases
Solution Approach 1:
The patent employs peptide ligands (9-20 amino acids) instead of expensive antibodies. These peptides are synthesized chemically rather than biologically, dramatically reducing manufacturing cost while maintaining tumor targeting capability through high affinity binding to ECM proteins like FN-EDB and TNC-C
Solution Approach 2:
The patent extracts the essential binding function from full-size antibodies and concentrates it into minimal peptide sequences. By identifying and using only the critical amino acid residues responsible for ECM protein binding, the patent creates simplified ligands that retain tumor homing capability without the unwanted properties of full antibodies
2Reliability
If antibodies are used as affinity ligands for targeting, then tumor site drug concentration is increased, but tissue penetration is reduced
Solution Approach 1:
The patent uses short peptide sequences (9-20 amino acids) compared to full antibodies (~150 amino acids). This reduced size enables the peptides to penetrate tumor tissue more effectively while maintaining high affinity binding to ECM proteins, thus improving both tumor site concentration and tissue penetration simultaneously
3Reliability
If conventional targeting approaches are used, then drug delivery is achieved, but selective binding to FN-EDB and TNC-C is insufficient
Solution Approach 1:
The patent identifies and utilizes specific local sequences within the ECM proteins (FN-EDB and TNC-C domains) as binding targets. By designing peptides that recognize these specific local structures, the patent achieves highly selective binding to tumor-associated ECM proteins while avoiding non-specific binding to normal tissue proteins
Solution Approach 2:
The patent employs in vivo phage display to evolve peptide ligands with optimized binding parameters. Through iterative selection and mutagenesis, the peptides achieve high affinity and specificity for FN-EDB and TNC-C, enabling precise targeting that conventional approaches cannot achieve
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptides enable selective binding to FN-EDB and TNC-C, enhancing drug delivery and diagnostic imaging in tumors, thereby improving treatment efficacy and visualization.
Implementation Method 1
peptides with specific amino acid sequences, such as PPRRGLIKLKTS, TSKQNSR, and AGRGRLVR, which can selectively bind to FN-EDB and/or TNC-C
Data Source
AI summary
Disclosed are compositions, compounds, and methods relating to peptides that can target and home to cancer, tumors, and extracellular matrix. This is based on the discovery of peptides that can specifically bind to fibronectin extra domain B (FN-EDB), tenascin-C C domain (TNC-C), or both.